Significance of Cannabinoid CB1 Receptors in Improgan Antinociception

Journal of Pain

Volumn 8, Issue 11, 2007, Pages 850-860

  Gehani, Neal C ^a   Nalwalk, Julia W ^a   Razdan, Raj K ^b   Martin, Billy R ^c   Sun, Xufung ^d   Wentland, Mark ^d   Abood, Mary E ^e   Hough, Lindsay B ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ORGANIX INC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Research Rensselaer Polytechnic Institute   (United States)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

analgesia; antinociception; Cannabinoid; CB1 receptor; improgan; rimonabant

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANTINOCICEPTIVE AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CIMETIDINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE 5' O (3 THIOTRIPHOSPHATE) S 35; HISTAMINE H2 RECEPTOR ANTAGONIST; IMPROGAN; O 1691; O 1876; O 848; RIMONABANT; UNCLASSIFIED DRUG; 1 CYANO 2 [2 [(4 IMIDAZOLYL)METHYL]ETHYL] 3 METHYLGUANIDINE; ANALGESIC AGENT; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; TAIL FLICK TEST; ANALYSIS OF VARIANCE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PHYSIOLOGY; REACTION TIME; SPRAGUE DAWLEY RAT; TIME;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; CIMETIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INJECTIONS, INTRAVENTRICULAR; MALE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, CANNABINOID, CB1; TIME FACTORS;

EID: 35549009267     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2007.05.015     Document Type: Article

References (35)

1. 1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 53 (1997) 207-214
2. Breivogel C.S., Griffin G., Di M.V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60 (2001) 155-163
3. D' Amour F., and Smith D. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72 (1941) 74-79
4. DiMarzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., and Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75 (2000) 2434-2444
5. Ford W.R., Honan S.A., White R., and Hiley C.R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135 (2002) 1191-1198
6. Fride E., Foox A., Rosenberg E., Faigenboim M., Cohen V., Barda L., Blau H., and Mechoulam R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a 'CB3' receptor. Eur J Pharmacol 461 (2003) 27-34
7. Griffin G., Atkinson P.J., Showalter V.M., Martin B.R., and Abood M.E. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 285 (1998) 553-560
8. Hajos N., and Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43 (2002) 503-510
9. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
10. Hough L.B., Nalwalk J.W., Barnes W.G., Leurs R., Menge W.M., Timmerman H., and Wentland M. A third life for burimamide: Discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists. Ann N Y Acad Sci 909 (2000) 25-40
11. Hough L.B., Nalwalk J.W., Chen Y., Schuller A., Zhu Y., Zhang J., Menge W.M., Leurs R., Timmerman H., and Pintar J.E. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res 880 (2000) 102-108
12. Hough L.B., Nalwalk J.W., Stadel R., Timmerman H., Leurs R., Paria B.C., Wang X., and Dey S.K. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of obligatory role for endocannabinoids acting at CB(1) receptors. J Pharmacol Exp Ther 303 (2002) 314-322
13. Hough L.B., Nalwalk J.W., Barnes W.G., Leurs R., Menge W.M., and Timmerman H. A third legacy for burimamide: Discovery and characterization of improgan and a new class of non-opioid analgesics derived from histamine antagonists. In: Watanabe T., Timmerman H., and Yanai K. (Eds). Histamine Research in the New Millenium (2001), Elsevier, Amsterdam, The Netherlands 237-242
14. Hough L.B., de Esch I.J.P., Janssen E., Phillips J., Svokos K., Kern B., Trachler J., Abood M.E., Leurs R., and Nalwalk J.W. Antinociceptive activity of chemical congeners of improgan: Optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology 51 (2006) 447-456
15. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 (2005) 3093-3098
16. Katoch-Rouse R., Pavlova O.A., Caulder T., Hoffman A.F., Mukhin A.G., and Horti A.G. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem 46 (2003) 642-645
17. Lichtman A.H., Cook S.A., and Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276 (1996) 585-593
18. McAllister S.D., Hurst D.P., Barnett-Norris J., Lynch D., Reggio P.H., and Abood M.E. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 279 (2004) 48024-48037
19. Meng I.D., Manning B.H., Martin W.J., and Fields H.L. An analgesia circuit activated by cannabinoids. Nature 395 (1998) 381-383
20. Monory K., Tzavara E.T., Lexime J., Ledent C., Parmentier M., Borsodi A., and Hanoune J. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem Biophys Res Commun 292 (2002) 231-235
21. Nalwalk J.W., Svokos K., Taraschenko O., Leurs R., Timmerman H., and Hough L.B. Activation of brain stem nuclei by improgan, a non-opioid analgesic. Brain Res 1021 (2004) 248-255
22. Nalwalk J.W., Svokos K., and Hough L.B. Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB(1) receptor. Neuropharmacology 549 (2006) 79-83
23. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-611
24. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76 (2005) 1307-1324
25. Pertwee R.G., Thomas A., Stevenson L.A., Maor Y., and Mechoulam R. Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48 (2005) 1139-1146
26. Pistis M., Perra S., Pillolla G., Melis M., Gessa G.L., and Muntoni A.L. Cannabinoids modulate neuronal firing in the rat basolateral amygdala: Evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 46 (2004) 115-125
27. Pommery N., Taverne T., Telliez A., Goossens L., Charlier C., Pommery J., Goossens J.F., Houssin R., Durant F., and Henichart J.P. New COX-2/5-LOX inhibitors: Apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. J Med Chem 47 (2004) 6195-6206
28. 1 receptor. Mol Pharmacol 68 (2005) 1484-1495
29. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J.C., and Le F.G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56 (1995) 1941-1947
30. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22 (2005) 371-379
31. Steenland H.W., Ko S.W., Wu L.J., and Zhuo M. Hot receptors in the brain. Mol Pain 2 (2006) 34. http://doi:10.1186/1744-8069-2-34 doi:10.1186/1744-8069-2-34
32. Thomas B.F., Francisco M.E., Seltzman H.H., Thomas J.B., Fix S.E., Schulz A.K., Gilliam A.F., Pertwee R.G., and Stevenson L.A. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem 13 (2005) 5463-5474
33. Wagner J.A., Varga K., Jarai Z., and Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 (1999) 429-434
34. Wiley J.L., Jefferson R.G., Grier M.C., Mahadevan A., Razdan R.K., and Martin B.R. Novel pyrazole cannabinoids: Insights into CB(1) receptor recognition and activation. J Pharmacol Exp Ther 296 (2001) 1013-1022
35. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di M.V., Julius D., and Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457